ライフサイエンスコーパス: postmenopausal women

1 reduced risk of breast cancer among pre- and postmenopausal women.

2 e vulnerabilities for ER(+) breast cancer in postmenopausal women.

3 trogen action and frequently occurs in older postmenopausal women.

4 C-reactive protein in both premenopausal and postmenopausal women.

5 have high rates of recurrence, especially in postmenopausal women.

6 is promising for preexposure prophylaxis in postmenopausal women.

7 ted with worsened breast cancer prognosis in postmenopausal women.

8 but not consistently in oestrogen-deficient postmenopausal women.

9 f hormone receptor-positive breast cancer in postmenopausal women.

10 vels of parathyroid hormone (PTH) in healthy postmenopausal women.

11 isk of death as a result of breast cancer in postmenopausal women.

12 primary preventive measures for, insomnia in postmenopausal women.

13 itable for application in this population of postmenopausal women.

14 sociations of ESH and T2D were based only in postmenopausal women.

15 increases the risk of endometrial cancer in postmenopausal women.

16 ial effect on bone turnover markers (BTM) in postmenopausal women.

17 primary prevention of chronic conditions in postmenopausal women.

18 eased risk of incident HF hospitalization in postmenopausal women.

19 eased breast cancer incidence in a cohort of postmenopausal women.

20 tive as a screening tool for osteoporosis in postmenopausal women.

21 has a negative impact on quality of life of postmenopausal women.

22 itable for application in this population of postmenopausal women.

23 idence and mortality among premenopausal and postmenopausal women.

24 compared with continuous use of letrozole in postmenopausal women.

25 d motivate programs for weight loss in obese postmenopausal women.

26 ciated with increased risk of diabetes among postmenopausal women.

27 opausal women and 61.7 (7.2) years among the postmenopausal women.

28 cancer risk factors among premenopausal and postmenopausal women.

29 women and 54.7% (95% CI, 46.5%-54.7%) among postmenopausal women.

30 nondairy, and vegetable origins) in healthy postmenopausal women.

31 higher compared to 13.8 +/- 11.8 pmol/L for postmenopausal women.

32 dence of and mortality by race/ethnicity for postmenopausal women.

33 th an increased risk of bladder cancer among postmenopausal women.

34 ine are not risk factors for hypertension in postmenopausal women.

35 in gallate (EGCG) on blood lipids in healthy postmenopausal women.

36 ted with risk of CRC in this large cohort of postmenopausal women.

37 LS mortality associated with strenuous PA in postmenopausal women.

38 were inversely associated with T2D in these postmenopausal women.

39 nal microbial communities of Black and White postmenopausal women.

40 end points in perimenopausal, menopausal, or postmenopausal women.

41 one-receptor-positive early breast cancer in postmenopausal women.

42 to determine the skeletal benefits of SCF in postmenopausal women.

43 servational Study (1993-2012), a US study of postmenopausal women.

44 her risk factors for CTS identified in these postmenopausal women.

45 ism for the increased ovarian cancer risk in postmenopausal women.

46 n on the risk of cancer in a large cohort of postmenopausal women.

47 premenopausal women but an increased risk in postmenopausal women.

48 , non-Hodgkin lymphoma, and breast cancer in postmenopausal women.

49 %, for women with no family history, and for postmenopausal women.

50 sion of the gene encoding NKB is elevated in postmenopausal women.

51 stance in black compared with white pre- and postmenopausal women.

52 is independently associated with CHIP among postmenopausal women.

53 diets could be a risk factor for insomnia in postmenopausal women.

54 ive protein levels in both premenopausal and postmenopausal women.

55 development of asthma in perimenopausal and postmenopausal women.

56 stratified by male, premenopausal women, and postmenopausal women.

57 (P = 0.01) and trochanter BMD (P = 0.007) in postmenopausal women.

58 4-wk intervention periods in 20 overweight, postmenopausal women.

59 ne (DPV) vaginal ring (VR) versus placebo in postmenopausal women.

60 efully considered before starting therapy in postmenopausal women.

61 ase were investigated in this study on older postmenopausal women.

62 ted to prevent ER(+) breast cancers in obese postmenopausal women.

63 ospective cohort of 65-y-old healthy men and postmenopausal women.

64 a composite of cardiovascular diseases among postmenopausal women.

65 ep duration is associated with longer LTL in postmenopausal women.

66 usly sedentary middle-aged and older men and postmenopausal women.

67 le in lowering endometrial cancer risk among postmenopausal women.

68 y present in plasma of obese versus nonobese postmenopausal women.

69 were safe, well tolerated, and acceptable in postmenopausal women.

70 We studied a subpopulation of 3,145 postmenopausal women (1,796 European-American (EA) and 1

71 Among postmenopausal women, 22.8% (95% CI, 18.3%-27.3%) of bre

72 ticenter, double-blind study of 115 healthy, postmenopausal women (45 to 75 years of age) from Novemb

73 e concentrations were measured in 80 men and postmenopausal women (48 men, 32 women, age 40-65 y) enr

74 eding trial that was conducted in 81 men and postmenopausal women [49 men and 32 women; age range: 40

75 A total of 2303 healthy postmenopausal women 55 years or older were randomized,

76 (-11.5%; 95% CI: -15.0, -8.0; p<0.0001) and postmenopausal women (-7.2%; 95% CI: -10.0, -4.3; p<0.00

77 f systemic hypertension increases sharply as postmenopausal women age.

78 study was completed by 45 overweight men and postmenopausal women [age 58.9 +/- 4.3 y, BMI 27.9 +/- 1

79 onsuming a Western-style diet, 49 men and 32 postmenopausal women [age range: 40-65 y, body mass inde

80 ion, and invasive breast cancer among 12,701 postmenopausal women aged >/=50 years in a Women's Healt

81 Postmenopausal women aged 18 years or older with histolo

82 Postmenopausal women aged 18 years or older with histolo

83 cebo-controlled, phase 2 study, we recruited postmenopausal women aged 18 years or older with oestrog

84 domized clinical trials that involved 27 347 postmenopausal women aged 50 through 79 years with no pr

85 Observational follow-up of US multiethnic postmenopausal women aged 50 to 79 years enrolled in 2 r

86 48 studies that enrolled men or postmenopausal women aged 50 years or older who were bei

87 is randomised controlled trial, we recruited postmenopausal women aged 50-74 years from 13 centres in

88 fication Trial.Participants comprised 48,835 postmenopausal women aged 50-79 y; 40% were randomly ass

89 All of the participants were postmenopausal women aged 50-79 years at baseline (1993-

90 A total of 67,130 postmenopausal women aged 50-79 years were followed for

91 on microsimulation model of osteoporosis for postmenopausal women aged 55 years or older was develope

92 , placebo-controlled, phase 3 FREEDOM trial, postmenopausal women aged 60-90 years with osteoporosis

93 le-blind, placebo-controlled, phase 2 trial, postmenopausal women aged at least 18 years with an East

94 3 trial (done in 130 UK hospitals) in which postmenopausal women aged at least 50 years with WHO per

95 acebo-controlled phase 2, study, we enrolled postmenopausal women (aged >=18 years) with histological

96 Eligible patients were postmenopausal women (aged >=60 years or aged <60 years

97 n's Health Initiative (WHI) enrolled 161 809 postmenopausal women, aged 50 to 79 years (mean [SD] age

98 e mortality, and other major endpoints among postmenopausal women, aged 50-79 years at HT initiation.

99 A total of 1016 postmenopausal women, aged 53 to 81 years, completed bas

100 In the WHI DM trial, 48,835 postmenopausal women, ages 50-79 years, with no prior br

101 olite of DEP) concentration (p < 0.05) among postmenopausal women; all six genes loaded on to one of

102 nd 18.4%, 12.7%, and 10.5%, respectively, in postmenopausal women.An interactive program for calculat

103 METHODS AND Data of 1023 postmenopausal women and 1124 men (>/=45 years) with car

104 BC count was measured at baseline in 160,117 postmenopausal women and again in year 3 in 74,375 parti

105 HDL function and composition in overweight, postmenopausal women and determine how changes in HDL co

106 d size in black compared with white pre- and postmenopausal women and determine the relationship betw

107 alent risk factor for both premenopausal and postmenopausal women and had the largest effect on the P

108 ctive strategy for osteoporosis screening in postmenopausal women and has the potential to prevent a

109 National Osteoporosis Foundation guidelines, postmenopausal women and men at least 50 y old with oste

110 In contrast, postmenopausal women and men showed consistently low lev

111 Obesity enhances breast cancer risk in postmenopausal women and premenopausal women with geneti

112 ssociation between the facial features of 97 postmenopausal women and their levels of OS biomarkers 8

113 for the prevention of chronic conditions in postmenopausal women and whether outcomes vary among wom

114 baseline hemoglobin was measured in 160,081 postmenopausal women and year 3 hemoglobin was measured

115 Insomnia is common in postmenopausal women, and disturbed sleep has been linke

116 ian cancer incidence is highest in peri- and postmenopausal women, and epidemiological studies have e

117 es of unmedicated naturally ovulating women, postmenopausal women, and men daily and determined urina

118 cholesterol-lowering medications.CVD risk in postmenopausal women appears to be sensitive to a change

119 Postmenopausal women are at higher risk for cardiovascul

120 For postmenopausal women, aromatase inhibitors (AIs) are the

121 , which indicates that CpdX could be used in postmenopausal women as an efficient "harmless" GC subst

122 he present study, self-reported intakes from postmenopausal women at 40 participating US clinical cen

123 estrogen receptor-positive breast cancer in postmenopausal women at increased risk for breast cancer

124 estrogen receptor-positive breast cancers in postmenopausal women at increased risk of developing bre

125 Postmenopausal women at increased risk of developing bre

126 In postmenopausal women at increased risk, the choice of en

127 Eligible women were postmenopausal women (at least 36 months since last mens

128 tive recruited a large prospective cohort of postmenopausal women between 1993 and 1998.

129 A total of 439 overweight/obese, healthy, postmenopausal women [body mass index (BMI) > 25 kg/m(2)

130 for osteoporosis and reduce fracture risk in postmenopausal women by up to 50%.

131 range of potential nutritional biomarkers in postmenopausal women by using a controlled feeding study

132 associations were particularly strong among postmenopausal women [ (CI: 0.57, 0.93) and (CI: 0.74, 0

133 In this secondary analysis of node-negative postmenopausal women, conducted in the era before mammog

134 A total of 109 postmenopausal women consumed 1 L of semiskimmed milk (1

135 tary pattern on the cardiovascular health of postmenopausal women continues to be of public health in

136 re favorable among premenopausal or recently postmenopausal women deserves further investigation.

137 Fifteen of the pre-, and 49 of the postmenopausal women developed ulcerative mucositis (p =

138 Data from 2223 postmenopausal women diagnosed with nonmetastatic breast

139 cent to the fracture site were obtained from postmenopausal women during fracture repair surgery (fra

140 th a total of 58146 premenopausal and 144600 postmenopausal women enrolled in the study.

141 We prospectively examined a cohort of 93,676 postmenopausal women enrolled in the Women's Health Init

142 Half of postmenopausal women experience genitourinary syndrome o

143 and HFrEF in a multiracial cohort of 42 170 postmenopausal women followed up for a mean of 13.2 year

144 h 3, 2003, and Feb 8, 2012, we enrolled 2980 postmenopausal women from 236 centres in 14 countries an

145 estionnaires between 1980 and 2014 in 75,180 postmenopausal women from the Nurses' Health Study, and

146 We included postmenopausal women from the UK Biobank (n=11 495) aged

147 (CaD) and fracture risk.Data from 5823 white postmenopausal women from the Women's Health Initiative

148 alized controlled feeding study in which 153 postmenopausal women from the Women's Health Initiative

149 Postmenopausal women from the Women's Health Initiative

150 The study population comprised 51,754 postmenopausal women from the Women's Health Initiative

151 However, among postmenopausal women, greater adherence to HEI-2010 (qua

152 In women with benign tissue, postmenopausal women had a higher PUFA (0.35 +/- 0.06 vs

153 The molecular basis of RUTI, especially in postmenopausal women, has remained unclear because model

154 Postmenopausal women have unique sociobiological human i

155 Among postmenopausal women, hormone therapy with CEE plus MPA

156 ent bladder cancers among a cohort of 34,708 postmenopausal women in Iowa (1986-2010).

157 king water and diet and bladder cancer among postmenopausal women in Iowa.

158 d with a modestly increased risk of FI among postmenopausal women in the Nurses' Health Study.

159 A total of 1 312 051 postmenopausal women in the UK Million Women Study, aged

160 Using large-scale cohort data from postmenopausal women in the Women's Health Initiative Da

161 blood pressure and incident hypertension in postmenopausal women in the Women's Health Initiative Ob

162 acid fractions in breast adipose tissue for postmenopausal women in whom BMI values are not correlat

163 Of 144 260 postmenopausal women included (mean [SD] age at enrollme

164 Of 74,750 postmenopausal women included in the study, 3,612 develo

165 in a very homogeneous population of healthy postmenopausal women, indicate that there is a beneficia

166 Conclusion Intentional weight loss in postmenopausal women is associated with a lower endometr

167 Estrogen-alone therapy in postmenopausal women is associated with a small but sign

168 For example, a lack of estrogens in postmenopausal women is associated with an increased ris

169 one therapy to prevent chronic conditions in postmenopausal women is associated with some benefits, t

170 of weight loss on endometrial cancer risk in postmenopausal women is limited.

171 benefits and the harms of hormone therapy in postmenopausal women is small to moderate.

172 findings of higher E2 levels in men than in postmenopausal women may suggest that decreased oestroge

173 tion between MHT and risk of FI among 55,828 postmenopausal women (mean age, 73 years) who participat

174 nd slightly obese individuals (30 men and 22 postmenopausal women, mean +/- SD age: 62 +/- 6 y) were

175 Results For postmenopausal women, MUFA was lower (0.38 +/- 0.06 vs 0

176 cases of invasive breast cancer developed in postmenopausal women (n = 121,700) in the Nurses' Health

177 Hypercholesterolemic postmenopausal women (n = 20, mean +/- SD age 64 +/- 7 y

178 Patients and Methods Postmenopausal women (N = 36,794) ages 50 to 79 years at

179 Among postmenopausal women not taking estrogen, DASH (score: 1

180 ely associated with BMD than AHEI or MeDS in postmenopausal women not taking estrogen.

181 In this multiracial cohort of postmenopausal women, obesity stands out as a significan

182 Conclusion In our observational cohort of postmenopausal women observed from 2004 to 2011, BP use,

183 We enrolled postmenopausal women of any age with hormone receptor-po

184 In a first-in-human study in postmenopausal women, once daily treatment with BAY 1214

185 plain the reduced breast cancer incidence in postmenopausal women over 60 who are taking conjugated e

186 y inversely associated with interleukin 6 in postmenopausal women (P = 0.03).

187 ersely associated with interleukin-6 only in postmenopausal women (p=0.04).

188 (95% CI: 0.91, 1.09) based on 1,172 cases in postmenopausal women; p-interaction=0.08].

189 35-50) and 10 normal weight (BMI 18.5-26.9) postmenopausal women paired by age and ethnicity.

190 Data of 3,117 postmenopausal women participants of the Rotterdam Study

191 Methods The study population included 64,438 postmenopausal women participating in the French E3N (Et

192 sonality in self-reported diet quality among postmenopausal women participating in the Women's Health

193 orectomy (BSO), and incidence of diabetes in postmenopausal women participating in the Women's Health

194 n (YM), young women (YW), older men (OM) and postmenopausal women (PMW); and (2) measured changes in

195 nd risk of colorectal cancer (CRC) in 87,042 postmenopausal women recruited from 1993-1998 by the Wom

196 ongitudinal prospective cohort evaluation of postmenopausal women recruited from 40 clinical centers.

197 group analyses revealed that high-performing postmenopausal women (relative to low and middle perform

198 In postmenopausal women, reporting of simple cysts greater

199 d 96.7 mg/L in men, premenopausal women, and postmenopausal women, respectively.

200 Shotgun sequencing of vaginal swabs from postmenopausal women self-identified as Black or White w

201 In postmenopausal women, serum PFOS was negatively associat

202 consumption of 2 whole eggs/d by overweight, postmenopausal women showed a significant increase in ch

203 Postmenopausal women showed enhanced bilateral hippocamp

204 delaying or reducing PD symptoms in men and postmenopausal women.SIGNIFICANCE STATEMENT The mechanis

205 The relative preponderance among postmenopausal women suggests that estrogen deprivation

206 With this strategy, 12.8% of postmenopausal women sustained hip fractures in their re

207 In postmenopausal women, the corresponding difference in ra

208 Among postmenopausal women, the effect was more pronounced in

209 ons can be detected in this population of US postmenopausal women, these differences are not substant

210 le-blinded trial was performed in 14 healthy postmenopausal women to compare doses of 0, 10, and 20 g

211 Ab) and RNA-sequencing of bone biopsies from postmenopausal women to identify osteoclast-secreted fac

212 In postmenopausal women, treatment with oestradiol appears

213 sis of urine and bladder biopsy samples from postmenopausal women undergoing cystoscopy with fulgurat

214 iated with serious adverse health effects in postmenopausal women, use of menopausal hormone therapy

215 CI of 2-year increments) with depression in postmenopausal women was shown for increasing age at men

216 In a prospective study of postmenopausal women, we found significant increases in

217 bone mineral density (BMD) loss in peri- and postmenopausal women.We systematically searched EMBASE a

218 ional data from three independent samples of postmenopausal women were analyzed, including women from

219 Pre- and postmenopausal women were examined separately, and furth

220 A total of 643 healthy postmenopausal women were stratified according to time s

221 02) were associated with lower CRP levels in postmenopausal women, whereas duration of OC use was pos

222 02) were associated with lower CRP levels in postmenopausal women, whereas only OC duration was posit

223 ficantly increased bone calcium retention in postmenopausal women, which improved the bone calcium ba

224 Postmenopausal women who had large cup-to-disc ratio wit

225 Treatment is generally recommended in postmenopausal women who have a bone mineral density T s

226 primary prevention of chronic conditions in postmenopausal women who have had a hysterectomy.

227 ry prevention of chronic conditions for most postmenopausal women who have had a hysterectomy.

228 This was a prospective cohort study with postmenopausal women who participated in the Women's Hea

229 lth Initiative RA Study (1993-2010), sampled postmenopausal women who reported RA at baseline (1993-1

230 blood pressures at annual visit 3 in 29,985 postmenopausal women who were not hypertensive at baseli

231 Among 27 347 postmenopausal women who were randomized in both trials

232 ndometrial and ovarian cancers among 108,136 postmenopausal women who were recruited in the US Women'

233 Data from 488 postmenopausal women with (1) histologic diagnosis of no

234 The study enrolled postmenopausal women with a diagnosis of MBC and prior e

235 The Task Force concluded that postmenopausal women with an estimated 5-year risk for b

236 ry prevention of chronic conditions for most postmenopausal women with an intact uterus and that estr

237 Methods: Ten newly diagnosed, postmenopausal women with biopsy confirmed breast cancer

238 Methods: Ten newly diagnosed postmenopausal women with biopsy-confirmed breast cancer

239 and Participants: A retrospective cohort of postmenopausal women with breast cancer diagnosed from J

240 4747 (89.8%) premenopausal and 12502 (95.1%) postmenopausal women with breast cancer had at least 1 b

241 arotid plaque composition in elderly men and postmenopausal women with carotid atherosclerosis, as we

242 study estimated rates of sexual distress in postmenopausal women with chronic insomnia and explored

243 Postmenopausal women with chronic insomnia endorse high

244 KD or were receiving dialysis (3 trials), or postmenopausal women with CKD (4 trials).

245 Participants were postmenopausal women with clinically detected node-negat

246 he estrogen exposure and deprivation period, postmenopausal women with drug-naive PD were divided int

247 l to compare anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ under

248 e-blind, phase III trial included AI-treated postmenopausal women with early-stage breast cancer and

249 Eligible patients were postmenopausal women with early-stage breast cancer taki

250 -blind trial, BIG 1-98, which enrolled 8,010 postmenopausal women with early-stage, hormone receptor-

251 bined with endocrine therapy is effective in postmenopausal women with endocrine-resistant, hormone r

252 one treatment plus 3 years of the other) for postmenopausal women with endocrine-responsive early bre

253 In a cohort of postmenopausal women with ER-positive DCIS, preoperative

254 Postmenopausal women with ER-positive primary BC and tum

255 We used multimodal imaging to compare 26 postmenopausal women with fibromyalgia with 25 healthy c

256 INTERPRETATION: In postmenopausal women with hormone receptor-positive brea

257 A total of 13273 postmenopausal women with hormone receptor-positive brea

258 ble-blind trial that randomly assigned 6,193 postmenopausal women with hormone receptor-positive earl

259 Postmenopausal women with hormone-positive ductal carcin

260 Postmenopausal women with hormone-positive ductal carcin

261 strozole offers another treatment option for postmenopausal women with hormone-receptor-positive DCIS

262 acy of anastrozole with that of tamoxifen in postmenopausal women with hormone-receptor-positive DCIS

263 than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive inva

264 -line or second-line treatments, or both, in postmenopausal women with hormone-receptor-positive, HER

265 rapies with or without targeted therapies in postmenopausal women with hormone-receptor-positive, HER

266 Methods Postmenopausal women with HR-positive and node-positive

267 ase 3 clinical trial (NCT00073528), in which postmenopausal women with HR-positive invasive breast ca

268 th letrozole for first-line treatment in 668 postmenopausal women with HR-positive, HER2-negative rec

269 Thus, postmenopausal women with insomnia may be especially vul

270 We included 3,393 premenopausal and 3,915 postmenopausal women with intact ovaries/uterus from the

271 We included 3,393 premenopausal and 3,915 postmenopausal women with intact ovaries/uterus from the

272 ative to the standard dose for both pre- and postmenopausal women with intraepithelial neoplasia are

273 odanacatib increases bone mineral density in postmenopausal women with low bone mass.

274 limus may be administered with exemestane to postmenopausal women with MBC whose disease progresses w

275 this randomized, open-label phase II trial, postmenopausal women with newly diagnosed operable estro

276 menopausal state confers fibrosis risk among postmenopausal women with nonalcoholic fatty liver disea

277 ime from menopause with fibrosis severity in postmenopausal women with nonalcoholic fatty liver disea

278 Postmenopausal women with nonalcoholic steatohepatitis a

279 d Methods The trial randomly assigned 48,835 postmenopausal women with normal mammograms and without

280 lpha-OH), and stimulated equol production in postmenopausal women with osteopenia.

281 We enrolled 4093 postmenopausal women with osteoporosis and a fragility f

282 -neutralizing antibody (Scl-Ab) indicated in postmenopausal women with osteoporosis at high risk for

283 In postmenopausal women with osteoporosis who were at high

284 rdiovascular events, specifically stroke, in postmenopausal women with osteoporosis.

285 b, which is widely used for the treatment of postmenopausal women with osteoporosis.

286 ety of odanacatib to reduce fracture risk in postmenopausal women with osteoporosis.

287 f therapeutic approaches to treating men and postmenopausal women with PD.

288 rates the association between ELF and CLD in postmenopausal women with risk factors for liver disease

289 RE) and its performance in predicting LRE in postmenopausal women with risk factors in a nested case-

290 Among 1367 US postmenopausal women with serum metabolomic data in the

291 Postmenopausal women with stage I-IIIA hormone receptor-

292 ncology Group (ACOSOG) Z1031A trial enrolled postmenopausal women with stage II or III ER-positive (A

293 n the US Pelvic Floor Disorders Network, 183 postmenopausal women with symptomatic uterovaginal prola

294 Across cohorts, CHIP prevalence in postmenopausal women with versus without a history of pr

295 Vs) in breast cancer susceptibility genes in postmenopausal women with vs without breast cancer to gu

296 bacterial disease (PNTM) often affects white postmenopausal women, with a tall and lean body habitus

297 depression-related metabolic alterations in postmenopausal women, with possible implications for lat

298 Among 1500 white and 1300 black postmenopausal women without cardiovascular disease from

299 Postmenopausal women without premature menopause served

300 This cohort (n = 101,504) included postmenopausal women without T2D who completed a baselin